PDS Biotechnology commences trial for head and neck squamous cell carcinoma
PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy and safety of Versamune HPV plus pembrolizumab for head and neck squamous cell carcinoma (HNSCC).
The combination therapy is intended for use as a first-line treatment of individuals with recurrent or metastatic HPV16-positive HNSCC.
According to the company, the open-label, global and controlled trial is structured for enrolling nearly 350 subjects. They will be assigned to either the investigational arm or to a control arm, receiving only pembrolizumab at a 2:1 ratio.
Overall survival is the primary endpoint, with secondary endpoints being progression-free survival, objective response rate, duration of response, and disease control rate.
Mayo Clinic Comprehensive Cancer Center Oncology, Head and Neck Disease Group associate professor Katharine Price is set to oversee the trial as principal investigator.
PDS Biotechnology CEO and president Frank Bedu-Addo said: 'We are thrilled to share that the first trial site has been initiated, and activation of additional clinical sites continues.
'Considering the strength and durability of the clinical responses in our VERSATILE-002 study, we are pleased to get this registrational trial underway. We are confident in the potential of our innovative combination therapy to improve patient outcomes and enhance the standard of care.'
Versamune HPV is a subcutaneous immunotherapy that has demonstrated 'potential' in stimulating high levels of HPV16-specific cluster of differentiation 8 +(CD8+) and CD4+ T cells, activating several immune pathways.
It received fast track designation from the US Food and Drug Administration (FDA). This status could result in a priority review for the biologics license application (BLA) when submitted.
This decision by the US regulator is supported by data from the multicentre VERSATILE-002 Phase II trial.
The company is advancing its lead programme in advanced HPV16-positive head and neck squamous cell cancers with the pivotal trial.
PDS stated that Versamune HPV is being developed not only in conjunction with a standard-of-care immune checkpoint inhibitor, but also in a triple combo therapy that includes the Interleukin-12 (IL-12) IL-12 fused antibody-drug conjugate (ADC), PDS01ADC, and a standard-of-care immune checkpoint inhibitor.
"PDS Biotechnology commences trial for head and neck squamous cell carcinoma" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
a day ago
- Axios
Why developers have stopped building apartments
The economics of building apartments in the Twin Cities doesn't work, and it could be a long time before it does. Why it matters: The metro area is already undersupplied on housing. A staggering decline in multifamily building could drive up prices in the years to come. By the numbers: After peaking at 15,500 in 2022, permits issued to begin apartment construction in the metro fell to 5,000 last year and are on an even slower pace this year, according to preliminary data from the U.S. Department of Housing and Urban Development. Zoom in: Sherman Associates has been one of the most prolific local developers in recent years, building hundreds of units in Minneapolis and beyond. The company doesn't have a single project under construction right now, and as CEO Chris Sherman told Axios, his Minneapolis firm can't make it work without public subsidies. State of play: While there can be some outliers, the typical cost to build a midrise apartment building (think four to five stories) has reached $320,000-$340,000 a unit, Sherman said. Meanwhile, the average price paid for Class A apartment buildings was $223,400 per unit last quarter, said Heidi Addo, a broker who sells multifamily communities for Michel Commercial Real Estate. This massive gap is a nonstarter for most developers, especially merchant builders, who develop apartment communities, fill them up with renters and then sell. The big picture: The three main reasons for the slowdown: Construction costs have risen nearly 40% since 2020, according to general contractor Mortenson's Construction Cost Index for Minneapolis. Interest rates have risen dramatically since 2022, and there's a correlation between them and what price sellers can get for apartments. When interest rates were historically low in 2022, the average sale price of apartments peaked at $285,000 per unit, according to a Michel Commercial Real Estate report. Rents have not kept up with rising costs. Asking rents in the metro increased only 1.4% year over year in March, to an average of $1,543 per unit, according to the report. Friction point: Sherman said apartment sales prices will have to eclipse $400,000 per unit before his firm begins building again, with the exception being projects that receive public subsidies, like the one they're working on in St. Louis Park. "The numbers are just upside down — and not by a little, but a lot," Sherman said. What we're watching: Both Addo and Sherman believe rent increases are coming. Addo is already tracking major hikes in areas of the metro where few units have been delivered in recent years, particularly the northern suburbs. Sherman said the sweet deals renters have been getting — like free months of rent for new leases — will be drying up soon.
New York Post
2 days ago
- New York Post
Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments
This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson's disease with over 96% accuracy, offering a low-cost way to identify the neurodegenerative disorder far earlier than now. A pilot study in the journal Nature Chemical Engineering unveiled the device, which looks much like a regular pen. 3 A patient with PD using the diagnostic pen for a writing task. Nature Chemical Engineering It's able pick up on subtle motor dysfunctions before they're visible to the naked eye, all by analyzing how people write. So, how does this futuristic fountain pen work? The tip is made of a flexible silicone material infused with magnetic particles, and it writes using a special ferrofluid ink that contains nanomagnets. As someone writes, pressure from the hand deforms the tip, causing changes in magnetic fields that produce electrical signals — like a Morse code of motor function. Those signals are then analyzed to detect the difference between healthy and Parkinson's-affected motor patterns. In tests with 16 participants — including 3 with Parkinson's — the system nailed the diagnosis with 96.22% accuracy. Even more impressive? The pen worked whether people wrote on paper or in the air, meaning it doesn't even require a surface. 3 Nature Chemical Engineering Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. This diagnostic pen is portable, inexpensive and doesn't rely on a neurologist to interpret results, making it a promising option for remote screenings, home use or even telehealth checkups. 'Our development of the diagnostic pen represents a low-cost, widely disseminable and reliable technology with the potential to improve PD diagnostics across large populations and resource-limited areas,' the researchers wrote. With further validation in a larger population, the device could be used not just for early diagnosis, but for ongoing symptom tracking and personalized treatment monitoring. 3 Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. highwaystarz – This is just the latest innovation aimed at tackling Parkinson's disease, which affects more than 10 million people worldwide and has no known cure. A recent study found that psilocybin — the psychedelic compound that gave 'magic mushrooms' their trippy reputation in the 1960s — showed serious promise for improving mood and motor function in people with Parkinson's disease. Tavapadon — a new drug that mimics dopamine by targeting certain receptors — has also shown promise in clinical trials by reducing motor fluctuations and maintaining symptom control with fewer side effects than traditional therapies. Produodopa — a continuous infusion therapy first administered in the UK — was approved by the US Food and Drug Administration last fall. Innovative approaches targeting the psychological aspects of the disease have been successful as well — with tandem cycling proving to be especially popular. Some New Yorkers even find relief by playing pingpong.
Yahoo
4 days ago
- Yahoo
HistoSonics completes pivotal histotripsy system trial enrolment
As reports of an acquisition by one of the leading players in the medical device space percolate, HistoSonics has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours. The US company's prospective, multi-centre, single-arm pivotal #HOPE4KIDNEY (NCT05820087) trial is designed to evaluate the effectiveness and safety of the Edison system for the destruction of kidney tissue by treating primary solid renal tumours. A total of 67 patients have been enrolled with a single, non-metastatic solid kidney mass ≤3cm. Patients will be treated with the Edison system and followed for five years post-procedure, with data at the 90-day evaluation point to be submitted in support of regulatory approval with the US Food and Drug Administration (FDA). The Edison system uses a technology called histotripsy, involving the delivery of non-thermal, non-invasive focused ultrasound waves to target and eliminate cancerous liver tissue. The system received de novo clearance from the US Food and Drug Administration (FDA) in 2023 and last month secured its first major insurance coverage from a new healthcare policy from Healthcare payor Blue Cross Blue Shield of Michigan (BCBSM) and health plan option Blue Care Network. HistoSonics' vision is for its Edison system to become a 'foundational, non-invasive' solution across a range of clinical applications, the company's CEO, Mike Blue stated. 'Completing enrolment in our pivotal kidney tumour trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumour types and indications,' said Blue. In May, Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet Clinical Need Authorisation (UCNA) under the UK's Innovative Devices Access Pathway (IDAP), launched by the UK Government in 2023 to help fast-track 'transformative medical technologies' into the healthcare system. As first reported by the Financial Times last month, HistoSonics is seeking a valuation of more than $2.5bn for a takeover of the company, with Medtronic, GE HealthCare and Johnson & Johnson (J&J), a longtime backer of HistoSonics, among the interested parties evaluating the business. J&J most recently participated in HistoSonics' $102m Series D funding round. "HistoSonics completes pivotal histotripsy system trial enrolment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
